- Types of Eczema
- Child Eczema
- Causes & Triggers
- Living with Eczema
- Eczema Products
- Get Involved
April 5, 2016 – We’re one step closer to a new treatment for moderate to severe atopic dermatitis! Dupilimab, the first biologic therapy for AD, has shown in recent clinical trials to significantly clear skin and reduce itch.
March 30, 2016 – Although psoriasis was once at the forefront of therapeutic advancements in dermatology, atopic dermatitis (AD) is now taking center stage with several new treatments in the pipeline.
February 29, 2016 – Early weaning, defined as the introduction of solid foods at 4 or 5 months of age, was inversely related to the risk of AD, with children weaned at 4 months having lower AD risk compared to those exclusively breastfed.
February 23, 2016 – The increased susceptibility of AD patients to skin and soft tissue infections with Staphylococcus aureus makes this an important topic to review with AD patients and their families. The importance of this topic is further underscored by the continued rise of MRSA and other antibiotic resistant bacteria.
February 22, 2016 – Itch in atopic dermatitis generally originates in the skin. Medical names for itch starting in the skin can be pruritus, dermatological itch, or pruritoceptive itch.
February 22, 2016 – This study compares bleach baths with water baths on skin barrier function in atopic dermatitis using a split-body method as control. Neither bleach baths nor tap water baths were shown to disrupt barrier function.
February 16, 2016 – Epidermal barrier impairment and altered immune system in atopic dermatitis (AD) may predispose to ultraviolet induced DNA damage.
February 11, 2016 – Late last month, NEA’s Board of Directors gathered together for the annual NEA Board retreat in San Francisco, California. This year’s retreat focused on both celebrating 2015 successes, and sharing a number of exciting 2016 initiatives that will advance NEA’s Roadmap strategic plan goals.
February 10, 2016 – In January, Anacor Pharmaceuticals, Inc. announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of crisaborole topical ointment, 2%.
February 10, 2016 – An editorial from Peter A. Lio, MD on the Aron Regime.